Abstract Library

#2287 Mitochondrial or Aerobic Glycolysis Oriented Metabolism May Define Pancreatic Neuroendocrine Tumors (PanNET) Resistance to mTOR-Targeting Therapies

Introduction: The mTOR inhibitor Everolimus is approved for the treatment of PanNET and no predictive biomarker is available. mTOR is a central node controlling mitochondrial and aerobic glycolytic metabolisms.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Cros J, Bucau M, Raffenne J, Soukeur M, Dumont F,

Keywords: mTOR, everolimus, pancreatic NET, metabolism,

#2215 Development of Multiplex Biomarker Assay to Subtype Pancreatic Neuroendocrine Tumors (PanNETs) with Distinct Prognosis and Mutations

Introduction: Overall 5-year survival for PanNETs ranges from 25-100%. The treatment paradigm for PanNETs largely based upon grades, which is significantly heterogeneous. We previously defined three molecular subtypes (distributed grades) of PanNETs using PanNETassigner signature. There is an unmet clinical need for prognostic and predictive biomarkers and clinically-relevant assays to complement grade and improve patient stratification.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Sadanandam A

Authors: Sadanandam A, Young K, Nyamundanda G, Ragulan C, Lawlor R,

Keywords: molecular subtypes, biomarker assay, clinical assay, patient prognosis, subtype-specific mutations, NanoString Technologies, low-cost assay, pancreatic neuroendocrine tumors, grades, PanNETassigner subtype, patient stratification, pnet,

#2083 Plasma Protein Kallikrein-14 Strongly Predicts Pronounced Chromogranin A (CgA) Response in Small Intestinal Neuroendocrine Tumor (NET) Patients after Somatostatin Analog (SSA) Treatment: The Nordic EXPLAIN Biomarker Study

Introduction: Predicting treatment response at an early stage in the treatment algorithm for NET is highly desirable.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Kjellman M

Authors: Kjellman M, Knigge u, Welin S, Grønbæk H, Thiis-Evensen E,

Keywords: Plasma Protein Biomarker,

#1872 Whole-Exome Sequencing (WES) of Samples from Patients (pts) Classified as Exceptional Responders (ER) vs Poor Responders (PO) to Targeted Therapies in Pancreatic Neuroendocrine Tumours (pNETs).

Introduction: Sunitinib (SU) and everolimus (EVE) changed the treatment landscape for patients with well-differentiated pNETs. However, no predictive biomarkers have been established for these drug

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Barriuso J, Lamarca A, McNamara M, Manoharan P, Moghadam S,

Keywords: pNETs, WES, everolimus, sunitinib,

#1557 Dual High Throughput Proteomic and Transcriptomic Screen for Predictive Biomarkers of Everolimus Sensitivity in Pancreatic NET

Introduction: mTOR inhibitor Everolimus is approved for the treatment of well-differentiated PNET. The heterogeneity of the response rate and the potential toxicity warrant predictive biomarkers.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: CROS J

Authors: Bucau M, Cros J, Raffenne J, Rebours V, Palazzo M,

Keywords: PNET, everolimus, predictive biomarkers,